Arbutus Biopharma Corp - ROE
ABUS
Price:
$4.635
Market Cap:
$915.59M
Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB-101, an oral PD-L1 inhibitor, which is in phase 1a/1b clinical trial that has the potential to reawaken patients’ HBV-specific immune response by inhibiting PD-L1. The company has licensing agreement with Alnylam Pharmaceuticals, Inc. to develop and commercialize products with LNP delivery technolo...[Read more]
Industry
Biotechnology
IPO Date
2007-07-26
Stock Exchange
NASDAQ
Ticker
ABUS
PE Ratio
[5.58]
ROE
[129.32%]
Current Ratio
[54.26]
Dividend Yield
[0%]
Enterprise Value
[895.79M]
Dividend History
The ROE as of August 2026 (TTM) for Arbutus Biopharma Corp (ABUS) is 129.32%
According to Arbutus Biopharma Corp’s latest financial reports and current stock price. The company's current ROE is 129.32%. This represents a change of 869.48% compared to the average of 13.34% of the last 4 quarters.
Arbutus Biopharma Corp (ABUS) Historical ROE (quarterly & annually)
How has ABUS ROE performed in the past?
The mean historical ROE of Arbutus Biopharma Corp over the last ten years is -81.78%. The current 129.32% ROE has changed -258.12% with respect to the historical average. Over the past ten years (40 quarters), ABUS's ROE was at its highest in in the March 2026 quarter at 65.22%. The ROE was at its lowest in in the December 2016 quarter at -107.73%.
Average
-81.78%
Median
-56.63%
Minimum
-211.32%
Maximum
-28.52%
Arbutus Biopharma Corp (ABUS) ROE by Quarter and Year
Discovering the peaks and valleys of Arbutus Biopharma Corp ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 1.60%
Maximum Annual ROE = -28.52%
Minimum Annual Increase = -75.56%
Minimum Annual ROE = -211.32%
| Year | ROE | Change |
|---|---|---|
| 2025 | -43.75% | -39.08% |
| 2024 | -71.81% | 4.51% |
| 2023 | -68.71% | 35.39% |
| 2022 | -50.75% | 12.78% |
| 2021 | -45.00% | -28.02% |
| 2020 | -62.52% | -70.42% |
| 2019 | -211.32% | 641.04% |
| 2018 | -28.52% | -38.34% |
| 2017 | -46.25% | -75.56% |
| 2016 | -189.21% | 1.60% |
Arbutus Biopharma Corp (ABUS) Average ROE
How has ABUS ROE performed in the past?
The current ROE of Arbutus Biopharma Corp (ABUS) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-61.42%
5-year avg
-56.01%
10-year avg
-81.78%
Arbutus Biopharma Corp (ABUS) ROE vs. Peers
How is ABUS’s ROE compared to its peers?
Arbutus Biopharma Corp’s ROE is greater than ARS Pharmaceuticals, Inc. (-153.61%), less than Nanobiotix S.A. (31.23%), greater than GH Research PLC (-19.83%), greater than Tango Therapeutics, Inc. (-41.54%), greater than Bicara Therapeutics Inc. Common Stock (-35.89%), greater than Septerna Inc (-9.44%), greater than EyePoint Pharmaceuticals, Inc. (-135.81%), greater than Kura Oncology, Inc. (-141.95%), less than ProKidney Corp. (7.40%), greater than Savara Inc. (-87.19%),
| Company | ROE | Market cap |
|---|---|---|
| -153.61% | $530.90M | |
| 31.23% | $2.01B | |
| -19.83% | $2.00B | |
| -41.54% | $3.64B | |
| -35.89% | $1.41B | |
| -9.44% | $1.77B | |
| -135.81% | $1.01B | |
| -141.95% | $827.38M | |
| 7.40% | $549.78M | |
| -87.19% | $1.12B |
Build a custom stock screener for Arbutus Biopharma Corp (ABUS) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Arbutus Biopharma Corp using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Arbutus Biopharma Corp (ABUS) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Arbutus Biopharma Corp or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Arbutus Biopharma Corp's ROE?
How is the ROE calculated for Arbutus Biopharma Corp (ABUS)?
What is the highest ROE for Arbutus Biopharma Corp (ABUS)?
What is the 3-year average ROE for Arbutus Biopharma Corp (ABUS)?
What is the 5-year average ROE for Arbutus Biopharma Corp (ABUS)?
How does the current ROE for Arbutus Biopharma Corp (ABUS) compare to its historical average?